Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADA Regimen in Myelofibrosis and MDS/MPD
NCT00274820Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2005
- Primary completion
- Sep 2007
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide, ascorbic acid, dexamethasone and thalidomide in primary myelofibrosis (PMF) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Response Rate at 6 months. Started Oct 2005; status: completed.
02
Drugs
arsenic trioxideascorbic aciddexamethasonethalidomide
03
Conditions
primary myelofibrosis (PMF)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT00274820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274820.